Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revcovi (EZN-2279) in ADA-SCID
NCT01420627Phase 3Completed
- Sponsor
- Leadiant Biosciences
- Start
- Jan 2014
- Primary completion
- Apr 2018
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of elapegademase in adenosine deaminase deficiency, severe combined immunodeficiency (SCID), sponsored by Leadiant Biosciences. Started Jan 2014; status: completed.
02
Drugs
elapegademase
03
Conditions
adenosine deaminase deficiencysevere combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT01420627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420627.